Shanghai RAAS Blood Products (SHE:002252) received the recommendation of China's National Medical Products Administration to include its SR604 injection in the Care Program - Extension project, according to a Shenzhen bourse filing on Tuesday.
One of the drug's targeted conditions is congenital factor VII deficiency.
The project is a pilot program for encouraging the development of drugs for rare diseases.
The Chinese blood products maker's shares rose 3% during the afternoon trade.